Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)

Alnylam Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 88.59% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 88.59% YoY) and the FY2025 annual result came in at $4.8 million, down 91.27% from the prior year.
• Current Deferred Revenue was $3.2 million for Q1 2026 at Alnylam Pharmaceuticals, down from $4.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $131.8 million in Q1 2022 and bottomed at $2.5 million in Q3 2025.
• A 5-year average of $56.4 million and a median of $55.5 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 144.04% — and 2025, when it slumped 96.42%.
• Alnylam Pharmaceuticals' Current Deferred Revenue stood at $42.1 million in 2022, then soared by 144.04% to $102.8 million in 2023, then tumbled by 46.01% to $55.5 million in 2024, then sank by 91.27% to $4.8 million in 2025, then slumped by 33.68% to $3.2 million in 2026.
• Business Quant data shows ALNY's Current Deferred Revenue at $3.2 million in Q1 2026, $4.8 million in Q4 2025, and $2.5 million in Q3 2025.